BioCryst Pharmaceuticals (BCRX) Earnings Date & Reports

Key Takeaways

• BioCryst reported third quarter 2026 total revenue of $180.3 million, up from $159.4 million a year earlier, beating the consensus estimate of roughly $165.4 million.
• Diluted earnings per share (EPS) came in at $0.14, above analyst expectations of $0.09, while net income of $37.9 million nearly tripled from $12.9 million in the prior-year quarter.
• ORLADEYO, the company's oral therapy for hereditary angioedema (HAE, a rare condition causing severe swelling), generated $174.8 million in quarterly revenue, up 20% year over year on a comparable basis.
• The company raised its full-year 2026 total revenue guidance to a range of $715 million to $730 million and tightened its non-GAAP operating expense outlook to $415 million to $425 million.
• Non-GAAP operating profit grew about 70% year over year, while cash and investments stood at roughly $376 million at quarter end.
• You can find more information about the ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to discover automated trading strategies and market insights.

Earnings Context and Why It Matters

BioCryst Pharmaceuticals is in the midst of a strategic evolution from a single-product HAE company into a broader rare-disease specialist. Its flagship ORLADEYO franchise remains the primary driver of revenue and profitability, while the pipeline — anchored by navenibart, acquired through the January 2026 purchase of Astria Therapeutics — represents the next potential growth phase. This report matters because it shows whether ORLADEYO's commercial momentum and operating discipline can keep funding that transition. Investors were also watching the August launch of ORLADEYO pellets for pediatric patients and the shift to CareMed as the company's sole specialty pharmacy partner, both of which could shape demand trends into 2027.

Reported Results

For the third quarter ended September 30, 2026, BioCryst reported total revenue of $180.3 million, compared with $159.4 million in the same period last year. ORLADEYO contributed $174.8 million of that total, while licensing and other revenues added $5.5 million. Diluted EPS was $0.14, ahead of the consensus estimate of $0.09, and revenue also topped the roughly $165.4 million Wall Street expected.

On a GAAP basis (generally accepted accounting principles), net income was $37.9 million, up from $12.9 million a year earlier. Non-GAAP operating profit reached approximately $86 million, an increase of about 70% year over year, while non-GAAP net income more than doubled to $71 million. The company ended the quarter with roughly $376 million in cash, equivalents, and investments.

Management raised full-year 2026 total revenue guidance to $715 million to $730 million, reflecting higher licensing revenue and international RAPIVAB orders, while keeping ORLADEYO revenue guidance unchanged at $625 million to $645 million. Non-GAAP operating expense guidance was tightened to $415 million to $425 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and emerging opportunities more efficiently than manual research. For those looking to complement earnings analysis with data-driven screening, the AI Screener offers a practical starting point for narrowing the investment universe.

Market Reaction and Investor Sentiment

BioCryst shares rose about 1.7% following the November 4 presentation, closing near $8.72 after the company beat on both revenue and EPS and raised its full-year outlook. Sentiment was supported by stronger-than-expected profitability and management's confidence in continued revenue growth alongside a lower cost base heading into 2027. That said, the third quarter benefited from an initial specialty pharmacy inventory build related to the CareMed transition, a factor management has described as a finite, one-time dynamic rather than a long-term operating trend. Investors are weighing that temporary lift against underlying demand strength and the early traction of the pediatric pellet launch.

Forward Outlook and Key Factors to Monitor

Looking ahead, BioCryst expects its business to keep growing revenue while operating expenses decline further in 2027 as the full benefit of 2026 cost actions is realized. Management has not yet issued formal 2027 guidance, but signaled that the combination of growth and efficiency should support continued expansion in profitability.

The most important near-term catalyst is navenibart, the long-acting injectable HAE candidate whose pivotal trial fully enrolled in June 2026. Top-line data are expected in the third quarter of 2027, and the outcome will be central to BioCryst's goal of serving both oral and injectable HAE patients.

Investors should also watch for early clinical data on BCX17725, an investigational therapy for Netherton syndrome, expected before year-end 2026, as well as the progress of the 150 mg ORLADEYO pellet launch for patients ages 12 and older. The CareMed pharmacy transition remains a factor to monitor, given the inventory dynamics that supported the third quarter. Each of these developments could shape the trajectory of revenue growth and profitability into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations